Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Enoxaparin in Psoriasis
NCT06416566Not yet recruiting
- Sponsor
- Zagazig University
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of enoxaparin in plaque psoriasis, sponsored by Zagazig University. Primary endpoint: Psoriatic Area and Severity Index. Planned start May 2024; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06416566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416566.